文献速递肾癌与肾肿瘤

T1a期肾细胞癌冷冻消融与热消融后的癌症特异性死亡率比较

Cancer-specific Mortality After Cryoablation vs Heat-based Thermal Ablation in T1a Renal Cell Carcinoma.
PubMed 文献 · J Urol · 2022-11-28

基于SEER数据库(2004-2018)的回顾性研究,比较cT1a期肾细胞癌患者接受冷冻消融与热消融后的癌症特异性死亡率。经倾向性评分匹配后,肿瘤大小3.1-4 cm组中热消融的癌症特异性死亡率显著高于冷冻消融(HR 2.02,P<.001);肿瘤≤3 cm组中两种技术无显著差异(HR 1.13,P=.5)。

要点

  • 肿瘤大小3.1-4 cm的cT1a患者,热消融后癌症特异性死亡风险约为冷冻消融的2倍(HR 2.02,P<.001)。
  • 肿瘤大小≤3 cm的cT1a患者,热消融与冷冻消融的癌症特异性死亡率无显著差异(HR 1.13,P=.5)。
  • 作者认为这些发现应纳入临床决策与知情同意。

核心结论

  • 在cT1a期、肿瘤大小3.1-4 cm患者中,热消融后的癌症特异性死亡率是冷冻消融的两倍。
  • 在肿瘤大小≤3 cm患者中,两种消融技术的有效性相当。
  • 作者认为这些发现应纳入临床决策和知情同意。

研究设计与样本

  • 回顾性队列研究,数据来自监测、流行病学和最终结果(SEER)数据库(2004-2018)。
  • 纳入临床T1a期肾细胞癌接受冷冻消融或热消融的患者。
  • 采用竞争风险回归模型,调整其他原因死亡及协变量(年龄、肿瘤大小、肿瘤分级、组织学亚型)。

主要发现

  • 肿瘤大小3.1-4 cm组共1468例可评估患者,冷冻消融1080例 vs 热消融388例;倾向性评分匹配后冷冻消融757例 vs 热消融388例。
  • 匹配后多变量竞争风险回归显示,热消融与更高的癌症特异性死亡率相关(HR 2.02,P<.001),相对于冷冻消融。
  • 肿瘤大小≤3 cm组共4468例可评估患者,冷冻消融3354例 vs 热消融1114例;匹配后冷冻消融2217例 vs 热消融1114例。
  • 匹配后多变量竞争风险回归显示,热消融与更高的癌症特异性死亡率无显著关联(HR 1.13,P=.5),相对于冷冻消融。

临床怎么用

  • 作者认为这些发现应在临床决策和知情同意中予以考虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Guidelines suggest less favorable cancer control outcomes for local tumor destruction in T1a renal cell carcinoma patients with tumor size 3.1-4 cm. We compared cancer-specific mortality between cryoablation vs heat-based thermal ablation in patients with tumor size 3.1-4 cm, as well as in patients with tumor size ≤3 cm. MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2018), we identified patients with clinical T1a stage renal cell carcinoma treated with cryoablation or heat-based thermal ablation. After up to 2:1 ratio propensity score matching between patients treated with cryoablation vs heat-based thermal ablation, we addressed cancer-specific mortality relying on competing risks regression models, adjusted for other-cause mortality and other covariates (age, tumor size, tumor grade, and histological subtype). RESULTS: Of 1,468 assessable patients with tumor size 3.1-4 cm, 1,080 vs 388 were treated with cryoablation vs heat-based thermal ablation, respectively. After up to 2:1 propensity score matching that resulted in 757 cryoablations vs 388 heat-based thermal ablations, in multivariable competing risks regression models, heat-based thermal ablation was associated with higher cancer-specific mortality (HR:2.02, P < .001), relative to cryoablation. Of 4,468 assessable patients with tumor size ≤3 cm, 3,354 vs 1,114 were treated with cryoablation vs heat-based thermal ablation, respectively. After up to 2:1 propensity score matching that resulted in 2,217 cryoablations vs 1,114 heat-based thermal ablations, in multivariable competing risks regression models, heat-based thermal ablation was not associated with higher cancer-specific mortality (HR:1.13, P = .5) relative to cryoablation. CONCLUSIONS: Our findings corroborated that in cT1a patients with tumor size 3.1-4 cm, cancer-specific mortality is twofold higher after heat-based thermal ablation vs cryoablation. Conversely, in patients with tumor size ≤3 cm either ablation technique is equally valid. These findings should be considered at clinical decision making and informed consent.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Sorce G, Hoeh B, Hohenhorst L, et al. Cancer-specific Mortality After Cryoablation vs Heat-based Thermal Ablation in T1a Renal Cell Carcinoma. J Urol. 2022. PMID: 36440817. doi:10.1097/JU.0000000000002984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。